EX-10.1


   

  UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

   

  FORM 8-K

   

  CURRENT REPORT

  Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

  	
	Date of Report (Date of earliest event reported): June 16, 2022



   

   

  Adicet Bio, Inc.

  (Exact name of Registrant as Specified in Its Charter)

   

   

  					
	Delaware
	001-38359
	81-3305277

	(State or Other Jurisdiction
of Incorporation)
	(Commission File Number)
	(IRS Employer
Identification No.)

	 
	 
	 
	 
	 

	200 Clarendon Street
Floor 6
	 

	Boston, Massachusetts
	 
	02116

	(Address of Principal Executive Offices)
	 
	(Zip Code)



   

  	
	Registrant’s Telephone Number, Including Area Code: (650) 503-9095



   

  	
	Not applicable



  (Former Name or Former Address, if Changed Since Last Report)

   

  Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

  ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  Securities registered pursuant to Section 12(b) of the Act:

  					
	
Title of each class
	 
	Trading
Symbol(s)
	 
	
Name of each exchange on which registered

	Common Stock, par value $0.0001 per share
	 
	ACET
	 
	The Nasdaq Global Market



  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

  Emerging growth company ☒

  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

   

   

  

  Item 1.01 Entry into a Material Definitive Agreement.

  On June 16, 2022, Adicet Therapeutics, Inc. (“Adicet Therapeutics”), a wholly-owned subsidiary of Adicet Bio, Inc., entered into the Second Amendment to Lease, by and between Adicet Therapeutics and Westport Office Park, LLC (the “Second Amendment”). The Second Amendment further amends the Lease Agreement, dated as of October 31, 2018, as amended on December 30, 2020, for the premises located at 1000 Bridge Parkway, Redwood City, California (“1000 Bridge Parkway”). The Second Amendment expands the space leased by Adicet Therapeutics at 1000 Bridge Parkway to include a portion of 1200 Bridge Parkway, increasing Adicet Therapeutics’ leased space by 12,204 square feet (the “Expansion Space”). Adicet Therapeutics will pay a monthly fee for the Expansion Space increasing annually from $73,224.00 to $78,439.38 over the thirty-six (36) month term of the Second Amendment. The Second Amendment also provides Adicet Therapeutics with an allowance to construct improvements to the Expansion Space. 

   

  The Second Amendment is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the description of the amendment is qualified in its entirety by reference to such exhibit.

  Item 9.01 Exhibits

  (d) Exhibits 

  			
	Exhibit No.
	 
	Description

	10.1
	 
	Second Amendment to Lease, dated as of June 16, 2022, between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC, as Landlord.

	104
	 
	Cover Page Interactive Data File (embedded within the Inline XBRL document)



   

   

  

  SIGNATURES

  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

  				
	 
	 
	 
	ADICET BIO, INC.

	 
	 
	 
	 

	Date:
	June 21, 2022
	By: 
	/s/ Nick Harvey

	 
	 
	   Name:
    Title:
	Nick Harvey
Chief Financial Officer